Comparative pharmacology of cisatracurium (51W89), atracurium, and five isomers in cats

被引:63
|
作者
Wastila, WB
Maehr, RB
Turner, GL
Hill, DA
Savarese, JJ
机构
[1] BURROUGHS WELLCOME CO,DIV PHARMACOL,RES TRIANGLE PK,NC 27709
[2] WELLCOME FDN LTD,CHEM DEV LABS,SEPARAT UNIT,DARTFORD,KENT,ENGLAND
[3] CORNELL MED CTR,NEW YORK HOSP,NEW YORK,NY
关键词
animals; cat; neuromuscular relaxants; neuromuscular blocking agents; atracurium; cisatracurium;
D O I
10.1097/00000542-199607000-00023
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Atracurium has four chiral centers and the marketed product is a mixture of ten optical and geometric isomers. Six of the isomers were prepared and evaluated for neuromuscular blocking activity and autonomic effects in anesthetized cats. This study reports the comparative pharmacology of the six isomers and atracurium that led to the selection of one isomer, cisatracurium (Nimbex, 51W89) for clinical development. Methods: Purpose bred cats, anesthetized with alpha-chloralose (80 mg/kg) and pentobarbital sodium (7 mg/kg) administered intraperitoneally, were used in this study. Neuromuscular blocking effects were assessed from the effects on the tibialis anterior twitch evoked at 0.15 Hz. Inhibition of the autonomic nervous system was assessed from the effects on the nictitating membrane contraction, in response to preganglionic sympathetic nerve stimulation and the bradycardia/vasodepressor responses to vagal nerve stimulation. Cardiovascular effects and plasma histamine concentrations were determined after a bolus injection of cisatracurium or atracurium. Results: Like atracurium, all six isomers produced dose-dependent neuromuscular block (NMB). The calculated ED(95) NMB values varied approximately tenfold (43 +/- 2 mu g/kg-488 +/- 56 mu g/kg). The ''R-series'' isomers were more potent than the corresponding ''S series'' isomers. With the exception of the S,Trans-S',Trans isomer, the NMB effects, i.e., onset times (range 2.6 +/- 0.2 min to 4.7 +/- 0.3 min) and total durations (range 9.9 +/- 1.4 min to 14 +/- 0.9 min), of the other five isomers were very similar to that of atracurium. The former isomer had a relatively short duration of action. The 25-75% recovery times after cisatracurium at 1X ED(95) (4.4 +/- 0.4 min), 4X ED(95) (4.5 +/- 0.4 min), and continuous infusions lasting at least 60 min that maintained 95-99% NMB (4.8 +/- 0.4 min) indicated a noncumulative effect. The vagal ID50: NMB ED(95) ratios for atracurium and the six isomers ranged from 2 to 27. The sympathetic ID25: NMB ED(95) ranged from 2.7 to 60. Atracurium and all of the isomers, except cisatracurium, produced cardiovascular effects after intravenous bolus administration at large doses (700-4,800 mu g/kg). In contrast to atracurium, there were no changes in plasma histamine concentrations associated with the administration of doses of cisatracurium equivalent to 60X the NMB ED(95) (62 +/- 8 mu g/kg). Conclusions: Cisatracurium has neuromuscular blocking effects identical to those of atracurium, is more potent, and does not produce cardiovascular effects or increase plasma histamine concentrations.
引用
收藏
页码:169 / 177
页数:9
相关论文
共 46 条
  • [31] INFUSION REQUIREMENTS OF PATIENTS RECEIVING 51W89 IN THE INTENSIVE-CARE UNIT
    STONE, AJ
    POLLARD, BJ
    HARPER, NJN
    BRITISH JOURNAL OF ANAESTHESIA, 1994, 72 (04) : P486 - P487
  • [32] CARDIOVASCULAR EFFECTS OF 51W89 UNDER NITROUS OXIDE-OPIOID-BARBITURATE ANESTHESIA
    LIEN, CA
    BELMONT, MR
    ABALOS, A
    QUESSY, S
    SAVARESE, JJ
    ANESTHESIA AND ANALGESIA, 1994, 78 (02): : U137 - U137
  • [33] EVALUATION OF 51W89 FOR ENDOTRACHEAL INTUBATION IN PATIENTS ANESTHETIZED WITH PROPOFOL AND NITROUS-OXIDE
    BLUESTEIN, LS
    STINSON, LW
    WILSON, RM
    LENNON, RL
    QUESSY, SN
    ANESTHESIOLOGY, 1993, 79 (3A) : A920 - A920
  • [34] Comparative clinical pharmacology of rocuronium, cisatracurium, and their combination (vol 89, pg 1116, 1998)
    Naquib, M
    Samarkandi, AH
    Ammar, A
    Elfaqih, SR
    AlZahrani, S
    Turkistani, A
    ANESTHESIOLOGY, 1999, 90 (04) : 1241 - 1241
  • [35] Pharmacodynamic dose-response and safety study of cisatracurium (51W89) in adult surgical patients during N2O-O-2-opioid anesthesia
    Lepage, JY
    Malinovsky, JM
    Malinge, M
    Lechevalier, T
    Dupuch, C
    Cozian, A
    Pinaud, M
    Souron, R
    ANESTHESIA AND ANALGESIA, 1996, 83 (04): : 823 - 829
  • [36] PHARMACOKINETICS OF 1R-CIS 1'R-CIS ATRACURIUM BESYLATE (51W89) AND PLASMA LAUDANOSINE CONCENTRATIONS IN HEALTH AND CHRONIC-RENAL-FAILURE
    EASTWOOD, NB
    BOYD, AH
    PARKER, CJR
    HUNTER, JM
    BRITISH JOURNAL OF ANAESTHESIA, 1995, 75 (04) : 431 - 435
  • [37] POPULATION PHARMACOKINETICS PHARMACODYNAMICS (PW/PD) OF 51W89, A NEW NEUROMUSCULAR BLOCKING-AGENT
    SCHMITH, VD
    FIEDLERKELLY, J
    PHILLIPS, L
    GRASELA, TH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (02) : 213 - 213
  • [38] 51W89 IN CHILDREN UNDER HALOTHANE AND N2O-O2-OPIOID ANESTHESIA
    MERETOJA, OA
    TAIVAINEN, T
    WIRTAVUORI, K
    ANESTHESIOLOGY, 1994, 81 (3A) : A1080 - A1080
  • [39] DOSE-RESPONSE RELATIONS OF 51W89 UNDER NITROUS-OXIDE-OPIOID-BARBITURATE ANESTHESIA
    LIEN, CA
    BELMONT, MR
    ABALOS, A
    ABOUDONIA, M
    SAVARESE, JJ
    ANESTHESIOLOGY, 1993, 79 (3A) : A948 - A948
  • [40] CONTINUOUS-INFUSION OF 51W89 IN PATIENTS UNDER NITROUS OXIDE-OPIOID-BARBITURATE ANESTHESIA
    BELMONT, M
    LIEN, C
    FAGAN, M
    QUESSY, S
    SAVARESE, J
    ANESTHESIA AND ANALGESIA, 1994, 78 (02): : U28 - U28